GLP-1s and Life Insurance: What Underwriters Actually Do
This is a financial-planning angle that rarely gets covered alongside the medical side of GLP-1s. Nothing here is insurance or medical advice - it is context for a conversation you should have with a licensed insurance professional and your prescriber.
The common underwriting practice
Life insurance applications ask about weight change in the past 12 months regardless of cause. Multiple insurance sources describe a common (though not universal) practice: insurers do not fully credit weight loss until it has held for roughly a year, and typically credit back around half the difference between your prior and current weight in the meantime - effectively underwriting you closer to the midpoint of the two weights.
This is not GLP-1-specific. It applies to weight loss from diet, surgery, or medication alike, because insurers have long observed that rapid weight loss is often not durable. Insurers refer to underpricing risk this way as "mortality slippage" - the concern that a current weight snapshot may not hold up over a 10-30 year policy term.
Why insurers are cautious specifically about GLP-1-driven loss
The concern traces partly to trial data on what happens after stopping: the STEP-1 trial extension found patients regained roughly two-thirds of lost weight within a year of discontinuing semaglutide, and broader 2026 research confirms regain is a real pattern (though real-world regain looks smaller than trial data once you account for people switching drugs or continuing treatment - see the full breakdown on what stopping a GLP-1 actually costs). An insurer pricing a policy for decades has reason to ask whether today's lower weight will still be true in five years, not just whether it is true today.
What to expect on the application
- Why the medication was prescribed (weight management vs. type 2 diabetes vs. another indication)
- How long you have been taking it
- Your weight before starting treatment, and your current weight
- Whether a physician is actively supervising the treatment
- Any other medications or conditions the GLP-1 is treating alongside weight (blood pressure, cholesterol, sleep apnea)
Answer accurately. Misrepresenting current medications on a life insurance application is a well-established basis for a later claim denial or policy rescission - the short-term rate benefit of omitting it is not worth that risk.
Practical takeaways
- If your weight has changed significantly and you can wait, holding your current weight for roughly a year before applying typically leads to a less-discounted underwriting outcome.
- If you need coverage sooner, an independent broker who shops multiple carriers can matter - underwriting guidelines and how current a carrier is on GLP-1-specific data both vary by insurer.
- If your GLP-1 use is treating a comorbidity insurers already price for (blood pressure, A1c, sleep apnea), documented improvement in that condition can help your case over time, separately from the weight-loss discounting question.
- Do not stop a GLP-1 specifically to influence an insurance application - that decision belongs with your prescriber, and stopping carries its own well-documented regain risk regardless of any insurance timeline.
Frequently asked questions
Does taking Ozempic or Wegovy get my life insurance application denied?
Rarely outright denied - but it can affect your rate class and how underwriters treat your current weight. Life insurance applications ask about weight loss in the past 12 months regardless of cause, and being on a GLP-1 for weight management specifically is likely to prompt follow-up questions: why it was prescribed, how long you have been taking it, your weight before starting, and whether a physician supervises the treatment. Being honest on the application matters - misrepresenting current medications on a life insurance application is a common basis for a later claim denial or rescission.
Why do underwriters discount recent weight loss at all?
Because insurers price a policy to last 10-30 years, and a snapshot of "current weight" is only useful if it predicts weight years from now. The common industry practice - reported by multiple insurance sources - is that underwriters do not fully credit weight loss until you have held the new weight for a full year, and in the meantime typically "credit back" roughly half the difference between your prior and current weight. This is not specific to GLP-1s; it applies to weight loss from any source (diet, surgery, medication) because insurers have long observed that rapid weight loss is often not durable. Insurers call misjudging this "mortality slippage" - underpricing risk because a snapshot didn't hold up.
Is the "add back half the weight" rule the same at every insurer?
No - treat it as a common practice, not a uniform rule you can rely on with every carrier. Underwriting guidelines vary by insurer, and some are more current on GLP-1-specific data than others. This is exactly the kind of variation an independent broker who shops multiple carriers can navigate - a single insurer's conservative stance is not necessarily every insurer's stance.
Does the reason I am taking a GLP-1 matter?
Likely yes. An applicant on Ozempic or Mounjaro for a documented type 2 diabetes diagnosis is in a different underwriting conversation than someone on Wegovy or Zepbound purely for weight management - diabetes itself is a separately-underwritten condition with its own rate classes, largely independent of the weight-loss discounting question. If your GLP-1 use is tied to resolving a comorbidity insurers already price for (like reducing A1c, blood pressure, or sleep apnea severity), that improvement can work in your favor over time, separate from the immediate post-weight-loss discount.
Should I wait to apply for life insurance until I have been on a GLP-1 for a year?
If your weight has changed significantly and is not yet stable, waiting until you have held your current weight for roughly 12 months typically gets you a more favorable, less-discounted underwriting outcome - this is the practical implication of the discounting practice described above, not personalized financial advice for your situation. If you need coverage sooner (a new mortgage, a new dependent), applying now and revisiting your rate class in a year, or working with a broker experienced in GLP-1 cases, are both reasonable paths - this is a conversation to have with a licensed insurance professional, not a decision to make from a blog post.
Does stopping the GLP-1 before applying help my application?
Not necessarily, and it is not medical advice this site would ever suggest. Stopping a GLP-1 specifically to influence an insurance application risks the well-documented regain that comes with discontinuation (see our full breakdown on what stopping a GLP-1 costs), and an underwriter asking about recent medication history would likely still see the gap and ask about it. Any decision to start, continue, or stop a GLP-1 belongs with you and your prescriber - not with an insurance timeline.
This page describes commonly-reported insurance industry practice as of July 2026, not a guarantee of how any specific insurer will underwrite your application. It is not insurance, financial, or medical advice - consult a licensed insurance professional for your specific situation.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.